BCAT1 and acute lymphoblastic leukemia: The combined action of BCAT1 inhibition and etoposide can selectively eliminate tumors in human xenograft models, suggesting that BCAT1 inhibitors may play an important role in the treatment of refractory T-ALL (Tosello et al., 2024).